- $342.96m
- $281.37m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 25.32 | ||
| Price to Tang. Book | 25.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -90.51% | ||
| Return on Equity | -169.81% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.19 | 1.49 | 1.26 | 1.56 | n/a | 3.25 | 30.85 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 1st, 2020
- Public Since
- September 22nd, 2020
- No. of Shareholders
- 195
- No. of Employees
- 183
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 119,083,728
- Address
- 2525 East North Carolina Highway 54, DURHAM, 27713
- Web
- https://humacyte.com/
- Phone
- +1 9193139633
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for HUMA
Humacyte Inc Annual Shareholders Meeting
Q2 2024 Humacyte Inc Earnings Release
Similar to HUMA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Humacyte share price?
As of Today at 19:10 UTC, shares in Humacyte are trading at $2.88. This share price information is delayed by 15 minutes.
How has the Humacyte share price performed this year?
Shares in Humacyte last closed at $2.88 and the price had moved by -12.99% over the past 365 days. In terms of relative price strength the Humacyte share price has underperformed the S&P500 Index by -29.73% over the past year.
What are the analyst and broker recommendations for Humacyte?
The overall consensus recommendation for Humacyte is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Humacyte dividend yield?
Humacyte does not currently pay a dividend.
Does Humacyte pay a dividend?
Humacyte does not currently pay a dividend.
When does Humacyte next pay dividends?
Humacyte does not currently pay a dividend.
How do I buy Humacyte shares?
To buy shares in Humacyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Humacyte?
As of the previous close price of $2.88, shares in Humacyte had a market capitalisation of $342.96m.
Where are Humacyte shares listed?
Here are the trading details for Humacyte:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: HUMA
What kind of share is Humacyte?
Based on an overall assessment of its quality, value and momentum Humacyte is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Humacyte share price forecast for 2024?
The analyst consensus target price for shares in Humacyte is $7.50. That is 160.42% above the last closing price of $2.88.
Analysts covering Humacyte currently have a consensus Earnings Per Share (EPS) forecast of -$0.90 for the next financial year.
What is the trend in the Humacyte share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Humacyte. Over the past six months, its share price has underperformed the S&P500 Index by -4.71%.
As of the last closing price of $2.88, shares in Humacyte were trading -6.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Humacyte PE Ratio?
The Humacyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Humacyte?
We do not have data on Humacyte's directors